Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome.

Rosenberger, Georg

Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome. [electronic resource] - Human mutation Mar 2009 - 352-62 p. digital

Publication Type: Journal Article

1098-1004

10.1002/humu.20855 doi


Abnormalities, Multiple--genetics
Cells, Cultured
Chromones--pharmacology
Craniofacial Abnormalities
Enzyme Inhibitors--pharmacology
Epidermal Growth Factor--pharmacology
Failure to Thrive--pathology
Fibroblasts--drug effects
Guanosine Triphosphate--metabolism
Humans
Immunoblotting
Intellectual Disability--pathology
MAP Kinase Kinase 1--metabolism
MAP Kinase Kinase 2--metabolism
Morpholines--pharmacology
Mutation
Phosphatidylinositol 3-Kinases--metabolism
Phosphoinositide-3 Kinase Inhibitors
Phosphorylation--drug effects
Proto-Oncogene Proteins c-akt--metabolism
Proto-Oncogene Proteins p21(ras)--genetics
Signal Transduction--drug effects
Skin--drug effects
Skin Abnormalities
Syndrome